INC bolsters its Phase I platform with new cardiac tech

INC Research ($INCR) added a new tool for early-stage safety studies, bringing in a new technology the company says will make Phase I cardiac trials more efficient. The FDA requires so-called QT testing for all novel cardio drugs, demanding data on how each agent affects the time between two intervals in the heart's electrical cycle. Such tests are often done separate from Phase I safety studies, adding a costly and time-consuming step to early development. INC, partnering with a company called iCardiac, now offers an integrated QT test that gathers the necessary data during standard Phase I trials. More

Suggested Articles

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.